2022 Annual Meeting
Optimization of Fluorescent Antigen in Mimix Patches
Vaxess is developing the MIMIX⢠microneedle platform to improve the vaccination experience and drive accessibility to immunity for all. Vaxessâs MIMIX⢠patch is a novel vaccination system designed for delivery of antigen into the skin, a target rich in antigen presenting cells. Once placed on the skin, each MIMIX⢠patch delivers a microarray of bioactive tips into the immunologically active dermal barrier. These bioactive tips are composed of a silk fibroin matrix that gradually dissolves into the body after the patch is removed. MIMIX immunization can be associated with numerous benefits including improved stability, dose-sparing, or enhanced magnitude/durability of immune response, with simplified administration. MIMIX⢠therapies are shelf-stable, do not require refrigeration, and can be simply applied, virtually pain free. One challenge of this platform is the ability to assess the number of needles that have been successfully inserted in the skin. The current method for characterizing deployment relies on an extensive conjugation of antigens of interest with a fluorescent dye, allowing visualization of the tips embedded in the skin as well quantification of total antigen embedded in excised skin. The drawback of this method is that potency of the antigen is reduced and therefore the relationship between the deployment efficiency and immunogenic effect cannot be properly established. Here, we describe a method of producing antigen that is fluorescently labeled, compatible with unique fluorescence assays, and remains highly potent throughout processing.